Provided by Tiger Fintech (Singapore) Pte. Ltd.

Opthea Ltd

3.41
+0.0000
Volume:- -
Turnover:- -
Market Cap:524.84M
PE:-1.62
High:3.41
Open:3.41
Low:3.41
Close:3.41
Loading ...

Company Profile

Company Name:
Opthea Ltd
Exchange:
NASDAQ
Establishment Date:
1984
Employees:
33
Office Location:
650 Chapel Street,Suite 0403, Level 4,South Yarra,Victoria,Australia
Zip Code:
3141
Fax:
61 3 9824 0083
Introduction:
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Directors

Name
Position
Jeremy Levin
Chairperson
Megan Baldwin
Chief Innovation Officer and Executive Director
Anshul Thakral
Director
Daniel Spiegelman
Director
Julia Haller
Director
Lawrence Gozlan
Director
Quinton Oswald
Director
Sujal Shah
Director
Susan Orr
Director

Shareholders

Name
Position
Fred Guerard
Chief Executive Officer
Bruno Gagnon
Senior Vice President Global Clinical Operations
Fang Li
Senior Vice President Regulatory
Julie Clark
Senior Vice President Clinical Development
Peter Lang
Chief Financial Officer
Joel Naor
Chief Medical Officer
Judith Robertson
Chief Commercial Officer
Karen Adams
Vice President Finance and Company Secretary
Kevin Bitter
Vice President, Strategy & Corporate Development
Mark O'Neill
Vice President Chemistry, Manufacturing and Controls
Megan Baldwin
Chief Innovation Officer and Executive Director